|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis Report - Hepatitis C Virus Q4 2010
Medpredict, Dec 2010, Pages: 122
This report summarizes the perspectives of six renowned Thought Leaders (5 US, 1 Italian) who specialize in the treatment of hepatitis C. The purpose of the conversations was 1) to understand the effect that the upcoming approvals of telaprevir and boceprevir will have on the treatment of HCV and 2) to predict how combination therapy will address the unmet needs still remaining after the approval of these protease inhibitors.
Some of the topics discussed by the panel:
- Goals of therapy
- Who should treat HCV
- Unmet needs and favorite future cocktails; IFN-sparing regimens
- Warehousing patients in the age of protease inhibitors
- Is resistance development a real problem?
- Dosing / compliance
- IL-28b / CC, CT and TT patients; US, EU and Asian populations
- Fibrosis score
- Possible reimbursement / bundling strategies
- Cost of therapy and duration of treatment
- Side effects: rash vs. anemia
This report provides essential strategic insight for key stakeholders in the hepatitis C virus market at a significant value versus customized primary research
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
